The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Sure, who wouldn’t want to lose a few pounds? But what’s really driving Hollywood’s latest trend is the drug’s seemingly miraculous side benefits ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Click here for more information. This just in! Ozempic’s out, and the Calocurb GLP-1 Activator Supplements are IN. When it comes to weight loss, finding a solution that works for you ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

The international formula was designed to deliver all the benefits of the US formula while meeting regulatory requirements ...